Ranking Invest

Cytokinetics, Incorporated

Segmento: Healthcare Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Indicadores Básicos

Valor de Mercado

$ 4.59 Bi

IVR

-0.45

IVR2

-0.38

Índices de Previsibilidade

Faturamento

1.61

Lucro

0.19

Margem

1.23

Índices de Tendência

Faturamento

-3.29

Lucro

-8.88

Margem

-5.99

Índices de Endividamento

DIV/PAT

-2.69

DIV/L4T

-1.17

Dívida Líquida

$ 717.38 Mi

Patrimônio Líquido

-$ 266.41 Mi

L4T

-$ 615.26 Mi

MM4T

-25834.70%

Dívidas
Dividendos
Cotação: $37.84

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre